Amazon coin set to soar 25X – starting December 16th?

This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024

Nicholas J. Valeriani net worth and biography

Nicholas Valeriani Biography and Net Worth

Director of Edwards Lifesciences

Nicholas J. Valeriani joined the board of directors in May 2016. Nicholas recently retired as the chief executive officer of West Health, The Gary and Mary West Health Institute, an independent nonprofit medical research organization that works to create new and more effective ways of delivering healthcare at lower costs, a position he has held since 2012. Previously, Nicholas served 34 years in key positions at Johnson & Johnson, including company group chairman of Johnson & Johnson Ortho-Clinical Diagnostics; vice president, office of strategy and growth; and as worldwide chairman, medical devices and diagnostics, and corporate vice president, human resources. Nicholas also served on the executive committee of Johnson & Johnson during his tenure. He currently serves on the board of directors of Edwards Lifesciences Corp., and Roka Bioscience, Inc., as well as the Robert Wood Johnson University Hospital. Nicholas received a bachelor’s degree in industrial engineering and a master of business administration from Rutgers University. Nicholas’s background in the global medical device industry and his leadership in the areas of strategy, growth and human resources provides our board of directors with valuable expertise in the industry.

What is Nicholas J. Valeriani's net worth?: The estimated net worth of Nicholas J. Valeriani is at least $5.08 million as of February 4th, 2021. Mr. Valeriani owns 67,896 shares of Edwards Lifesciences stock worth more than $5,079,300 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Valeriani may own. Learn More about Nicholas J. Valeriani's net worth.
How do I contact Nicholas J. Valeriani?: The corporate mailing address for Mr. Valeriani and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected]. Learn More on Nicholas J. Valeriani's contact information.
Has Nicholas J. Valeriani been buying or selling shares of Edwards Lifesciences?: Nicholas J. Valeriani has not been actively trading shares of Edwards Lifesciences during the last quarter. Most recently, on Wednesday, November 24th, Nicholas J. Valeriani bought 1,500 shares of Edwards Lifesciences stock. The stock was acquired at an average cost of $112.23 per share, with a total value of $168,345.00. Learn More on Nicholas J. Valeriani's trading history.
Who are Edwards Lifesciences' active insiders?: Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Daniel Lippis (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?: In the last year, Edwards Lifesciences insiders bought shares 1 times. They purchased a total of 580 shares worth more than $49,729.20. In the last year, insiders at the medical research company sold shares 34 times. They sold a total of 377,713 shares worth more than $31,439,247.64. The most recent insider tranaction occured on December, 16th when VP Daniel J Lippis sold 2,500 shares worth more than $185,200.00. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.
Information on this page was last updated on 12/16/2024.

Nicholas J. Valeriani Insider Trading History at Edwards Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/24/2021	Buy	1,500	$112.23	$168,345.00
2/4/2021	Sell	8,200	$85.21	$698,722.00	67,896

Nicholas J. Valeriani Buying and Selling Activity at Edwards Lifesciences

Edwards Lifesciences Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Today's Range

Now: $74.81

$72.97

$75.27

50 Day Range

MA: $70.06

$65.75

$74.81

2 Week Range

Now: $74.81

$58.93

$96.12

Volume

14,033,775 shs

Average Volume

4,725,668 shs

Market Capitalization

$44.12 billion

P/E Ratio

10.80

Dividend Yield

N/A

Beta

1.12

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.